Trevena (NASDAQ: TRVN) is one of 290 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its competitors? We will compare Trevena to related businesses based on the strength of its analyst recommendations, profitability, institutional ownership, dividends, earnings, valuation and risk.

Insider & Institutional Ownership

56.1% of Trevena shares are held by institutional investors. Comparatively, 49.6% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 4.6% of Trevena shares are held by insiders. Comparatively, 16.9% of shares of all “Bio Therapeutic Drugs” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.


This table compares Trevena and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Trevena N/A -150.22% -94.66%
Trevena Competitors -5,375.04% -161.60% -36.20%

Analyst Recommendations

This is a summary of current ratings for Trevena and its competitors, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Trevena 0 1 9 0 2.90
Trevena Competitors 1136 3439 11941 241 2.67

Trevena presently has a consensus price target of $8.65, suggesting a potential upside of 402.91%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 41.84%. Given Trevena’s stronger consensus rating and higher possible upside, research analysts clearly believe Trevena is more favorable than its competitors.

Earnings & Valuation

This table compares Trevena and its competitors revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Trevena $3.75 million -$102.99 million -1.04
Trevena Competitors $290.27 million $35.99 million 54.43

Trevena’s competitors have higher revenue and earnings than Trevena. Trevena is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Risk & Volatility

Trevena has a beta of -0.58, meaning that its share price is 158% less volatile than the S&P 500. Comparatively, Trevena’s competitors have a beta of 2.40, meaning that their average share price is 140% more volatile than the S&P 500.


Trevena competitors beat Trevena on 7 of the 13 factors compared.

About Trevena

Trevena Inc. is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers. It is also developing TRV250, a G protein biased ligand targeting the o-receptor, as a compound with a non-narcotic mechanism for the treatment of migraine. TRV250 also may have utility in a range of other central nervous system (CNS) indications. It is focused on commencing a Phase I study of TRV250 in the United Kingdom. Its ABLE product platform is a collection of biological information, in vitro assays, know-how and expertise that it uses to identify unique G protein coupled receptors (GPCR)-targeted biased ligands with various pharmaceutical properties.

Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with's FREE daily email newsletter.